A phase i study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 3, 2011, Pages 511-517

  Hill, Marisa E ^a   Li, Xiaobai ^a   Kim, Sharon ^a   Campbell, Angela ^a   Culler, Kristy ^a   Bloomston, Mark ^a   Zalupski, Mark ^b   Hejna, Gwen ^b   Bekaii Saab, Tanios ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Adenocarcinoma; Capecitabine; Docetaxel; Gemcitabine; Pancreas

Indexed keywords

CAPECITABINE; DOCETAXEL; GEMCITABINE; ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; TAXOID;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER INHIBITION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; ADENOCARCINOMA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL; TAXOIDS;

EID: 79953774928     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1348-3     Document Type: Article

References (23)

1. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics CA Cancer J Clin 59 4 225 249 10.3322/caac.20006 19474385
2. HA Burris III MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 2403 2413 1:CAS:528:DyaK2sXlsFKksLY%3D 9196156 (Pubitemid 27251144)
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Ding K, Ptaszynski M, Parulekar W (2005) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). In: Proceedings of ASCO 2005
4. K Kosuri P Muscarella TS Bekaii-Saab 2006 Updates and controversies in the treatment of pancreatic cancer Clin Adv Hematol Oncol 4 1 47 54 16562370 (Pubitemid 43173714)
5. K Pliarchopoulou D Pectasides 2009 Pancreatic cancer: current and future treatment strategies Cancer Treat Rev 35 5 431 436 1:STN:280: DC%2BD1MrjtleitQ%3D%3D 10.1016/j.ctrv.2009.02.005 19328630
6. G Lopes CMR Lima 2005 Docetaxel in the management of advanced pancreatic cancer Semin Oncol 32 2 Suppl 4 S10 S23 1:CAS:528:DC%2BD2MXlvVSjtb8%3D 10.1053/j.seminoncol.2005.04.003 16015551 (Pubitemid 40726040)
7. M Ducreux V Boige D Malka 2004 Emerging drugs in pancreatic cancer Expert Opin Emerg Drugs 9 1 73 78 1:CAS:528:DC%2BD2cXkt1Ggt7s%3D 10.1517/14728214.9.1. 73 15155137 (Pubitemid 38715579)
8. TH Cartwright A Cohn JA Varkey YM Chen TP Szatrowski JV Cox JJ Schulz 2002 Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer J Clin Oncol 20 1 160 164 1:CAS:528:DC%2BD38XnsFertA%3D%3D 10.1200/JCO.20.1.160 11773165 (Pubitemid 34032607)
9. D Cunningham I Chau DD Stocken JW Valle D Smith W Steward PG Harper J Dunn C Tudur-Smith J West S Falk A Crellin F Adab J Thompson P Leonard J Ostrowski M Eatock W Scheithauer R Herrmann JP Neoptolemos 2009 Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 33 5513 5518 1:CAS:528:DC%2BC3cXhtVWitrc%3D 10.1200/JCO.2009.24.2446 19858379
10. RL Fine DR Fogelman SM Schreibman M Desai W Sherman J Strauss S Guba R Andrade J Chabot 2008 The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis Cancer Chemother Pharmacol 61 1 167 175 1:CAS:528:DC%2BD2sXhtFSrtbbK 10.1007/s00280-007-0473-0 17440727 (Pubitemid 47512638)
11. N Sawada T Ishikawa Y Fukase M Nishida T Yoshikubo H Ishitsuka 1998 Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts Clin Cancer Res 4 4 1013 1019 1:CAS:528:DyaK1cXisFeksr4%3D 9563897 (Pubitemid 28183404)
12. T Kindwall-Keller GA Otterson D Young A Neki T Criswell G Nuovo R Soong R Diasio MA Villalona-Calero 2005 Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer Clin Cancer Res 11 5 1870 1876 1:CAS:528:DC%2BD2MXitVKrsLw%3D 10.1158/1078-0432.CCR- 04-1727 15756012 (Pubitemid 40471852)
13. P Nadell C Shapiro GA Otterson M Hauger S Erdal E Kraut S Clinton M Shah M Stanek P Monk MA Villalona-Calero 2002 Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies J Clin Oncol 20 11 2616 2623 10.1200/JCO.2002.22.030 (Pubitemid 34575633)
14. Q Ren V Kao JL Grem 1998 Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxyuridine in HT-29 colon cancer cells Clin Cancer Res 4 11 2811 2818 1:CAS:528:DyaK1cXns1Ogurc%3D 9829747 (Pubitemid 28523510)
15. M Tempero W Plunkett V Ruiz Van Haperen J Hainsworth H Hochster R Lenzi J Abbruzzese 2003 Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 18 3402 3408 1:CAS:528:DC%2BD2cXpsVKjtLs%3D 10.1200/JCO.2003.09.140 12885837 (Pubitemid 46594072)
16. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
17. GP Stathopoulos K Syrigos A Polyzos G Fountzilas SK Rigatos N Ziras A Potamiannou I Tsiakopoulos N Androulakis G Aravantinos A Athanasiadis P Papakotoulas V Georgoulias 2004 Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study Ann Oncol 15 2 224 229 1:STN:280: DC%2BD2c%2FlvVanug%3D%3D 10.1093/annonc/mdh065 14760113 (Pubitemid 38262619)
18. R Herrmann G Bodoky T Ruhstaller B Glimelius E Bajetta J Schüller P Saletti J Bauer A Figer B Pestalozzi CH Köhne W Mingrone S Stemmer K Tàmas V Kornek D Koeberle S Cina J Bernhard D Dietrich W Scheithauer 2007 Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group J Clin Oncol 25 16 2212 2217 1:CAS:528:DC%2BD2sXnsVShtbw%3D 10.1200/JCO.2006.09.0886 17538165 (Pubitemid 46954645)
19. AH Ko J Hwang AP Venook JL Abbruzzese EK Bergsland MA Tempero 2005 Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer Br J Cancer 93 2 195 199 1:CAS:528:DC%2BD2MXmt1yhurs%3D 10.1038/sj.bjc.6602687 15999098 (Pubitemid 41133205)
20. JD Allendorf M Lauerman A Bill M DiGiorgi N Goetz E Vakiani H Remotti B Schrope W Sherman M Hall RL Fine JA Chabot 2008 Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival J Gastrointest Surg 12 1 91 100 10.1007/s11605-007-0296-7 17786524
21. RB Adams PJ Allen 2009 Surgical treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Evans et al Ann Surg Oncol 16 7 1745 1750 10.1245/s10434-009-0410-z 19396494
22. T Furukawa 2008 Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside J Gastroenterol 43 12 905 911 1:CAS:528:DC%2BD1cXhsFejt73P 10.1007/s00535-008-2226-1 19107333
23. HH Wong NR Lemoine 2009 Pancreatic cancer: molecular pathogenesis and new therapeutic targets Nat Rev Gastroenterol Hepatol 6 7 412 422 1:CAS:528:DC%2BD1MXot12ltLo%3D 10.1038/nrgastro.2009.89 19506583